HLA-DPA1 anticorps (AA 29-222)
-
- Antigène Voir toutes HLA-DPA1 Anticorps
- HLA-DPA1 (Major Histocompatibility Complex, Class II, DP alpha 1 (HLA-DPA1))
-
Épitope
- AA 29-222
-
Reactivité
- Humain
-
Hôte
- Lapin
-
Clonalité
- Polyclonal
-
Conjugué
- Cet anticorp HLA-DPA1 est non-conjugé
-
Application
- Western Blotting (WB), ELISA, Immunofluorescence (IF)
- Réactivité croisée
- Humain
- Purification
- >95%, Protein G purified
- Immunogène
- Recombinant Human HLA class II histocompatibility antigen, DP alpha 1 chain protein (29-222AA)
- Isotype
- IgG
- Top Product
- Discover our top product HLA-DPA1 Anticorps primaire
-
-
- Indications d'application
- Recommended dilution: WB:1:1000-1:5000, IF:1:50-1:200,
- Restrictions
- For Research Use only
-
- Format
- Liquid
- Buffer
-
Preservative: 0.03 % Proclin 300
Constituents: 50 % Glycerol, 0.01M PBS, PH 7.4 - Agent conservateur
- ProClin
- Précaution d'utilisation
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Stock
- -20 °C,-80 °C
- Stockage commentaire
- Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
-
- Antigène
- HLA-DPA1 (Major Histocompatibility Complex, Class II, DP alpha 1 (HLA-DPA1))
- Autre désignation
- HLA-DPA1 (HLA-DPA1 Produits)
- Synonymes
- anticorps DP(W3), anticorps DP(W4), anticorps HLA-DP1A, anticorps HLADP, anticorps HLASB, anticorps PLT1, anticorps major histocompatibility complex, class II, DP alpha 1, anticorps HLA-DPA1
- Sujet
-
Background: Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accommodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments, exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs, other cells of the gastrointestinal tract, such as epithelial cells, express MHC class II molecules and CD74 and act as APCs, which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen, three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form a heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen processing occurs, CD74 undergoes a sequential degradation by various proteases, including CTSS and CTSL, leaving a small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell membrane surface. In B-cells, the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal miroenvironment has been implicated in the regulation of antigen loading into MHC II molecules, increased acidification produces increased proteolysis and efficient peptide loading.
Aliases: HLA-DPA1 antibody, HLA-DP1A antibody, HLASBHLA class II histocompatibility antigen antibody, DP alpha 1 chain antibody, DP(W3) antibody, DP(W4) antibody, HLA-SB alpha chain antibody, MHC class II DP3-alpha antibody, MHC class II DPA1 antibody
- UniProt
- P20036
- Pathways
- TCR Signaling, Cancer Immune Checkpoints, Human Leukocyte Antigen (HLA) in Adaptive Immune Response
-